Depleting Intratumoral CD4+CD25+ Regulatory T Cells via FasL Protein Transfer Enhances the Therapeutic Efficacy of Adoptive T Cell Transfer
Open Access
- 1 February 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (3) , 1291-1298
Abstract
One strategy for improving adoptive therapy is preconditioning the host immune environment by depleting CD4+CD25+ regulatory T cells (Treg) suppressive to antitumor responses. Given that Treg increase, or selectively accumulate, within tumors and are sensitive to FasL-mediated apoptosis, we test here the hypothesis that inducing apoptosis of intratumoral Treg using FasL may improve adoptive T cell therapy. We show that FasL applied intratumorally via protein transfer decreases intratumoral Treg via inducing apoptosis in these cells. Significantly, we show that the use of FasL prior to the infusion of tumor-reactive CD8+ T cells enhances the therapeutic efficacy of adoptive T cell transfer against established tumors, which is mediated by persistent, systemic antitumor immunity. Intratumoral FasL protein transfer also results in neutrophil infiltration of tumor. However, we show that intratumoral immunodepletion of neutrophils does not abolish the effect of FasL on adoptive transfer. Rather, the effect of FasL is completely abolished by cotransfer of Treg, isolated from the tumor-draining lymph nodes. Hence, our study shows for the first time that using FasL to predeplete intratumoral Treg provides a useful means for optimizing adoptive therapy. [Cancer Res 2007;67(3):1291–8]Keywords
This publication has 33 references indexed in Scilit:
- Arming Tumor-Reactive T Cells with Costimulator B7-1 Enhances Therapeutic Efficacy of the T CellsCancer Research, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumorsJournal of Experimental Medicine, 2005
- Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapyTrends in Immunology, 2005
- Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T CellsJournal of Experimental Medicine, 2004
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- Tumor-Specific Human CD4+ Regulatory T Cells and Their LigandsImmunity, 2004
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Fas receptor‐mediated apoptosis: a clinical application?The Journal of Pathology, 2001
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.Journal of Experimental Medicine, 1982